Prospective study comparing hepatic steatosis assessment by magnetic resonance imaging and four ultrasound methods in 105 successive patients

Table 2 Characteristics of steatotic and non-steatotic patients, n (%)

	Patients with steatosis (n = 85)	Patients without steatosis (n = 20)	P value
Demographic and anthropometric data
Sex (male)	40 (47)	11 (55)	0.62
Age (yr)	56 ± 14	53 ± 14	0.5
BMI (kg/m2)	31 ± 5	28 ± 6	0.0004
Normal BMI	7 (8)	4 (20)
Overweight	31 (37)	13 (65)
Obesity	47 (55)	3 (15)
Waist circumference (cm)1	108 ± 14	99 ± 15	0.004
Diabetes	33 (39)	5 (25)	0.3
Hypertension	37 (44)	5 (25)	0.2
Metabolic syndrome	65 (76)	8 (40)	0.0026
Biological data
Platelets count (G/L)1	236 ± 71	213 ± 78	0.2
AST (U/L)1	37 ± 30	27 ± 10	0.13
ALT (U/L)1	37 ± 30	49 ± 29	0.044
GGT (U/L)1	68 ± 53	116 ± 85	0.68
Triglycerides (g/L)1	1.8 ± 0.9	1.3 ± 0.9	0.0058
HDL cholesterol (g/L)1	1.3 ± 0.4	1.3 ± 0.3	0.1
Ferritin (ng/mL)1	121 ± 134	172 ± 127	0.45
Steatosis assessment
PDFF (%)1	18 ± 9	2 ± 3	< 0.0001
Fibroscan®
Technical success	84 (99)	20 (100)
cCAP (dB/m)	296 ± 42	246 ± 67	< 0.0001
Liver stiffness (KPa)1	8 ± 8	7 ± 5	NS
Liver stiffness > 10 KPa	19 (22)	2 (10)
Use of M probe	65 (76)	18 (90)
Use of XL probe	20 (24)	2 (10)
Aixplorer MACH 30®
Technical success	85 (100)	20 (100)
SSE (m/s)1	1515 ± 22	1533 ± 19	0.0009
AC (dB/cm/MHz)1	0.5 ± 0.1	0.39 ± 0.1	< 0.0001
HRI	1.52 ± 0.24	1.1 ± 0.18	< 0.0001
Technical success	84 (99)	20 (100)

¹Data are mean ± SD.

BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; PDFF: Proton density fat fraction; cCAP: Continuous controlled attenuation parameter; SSE: Sound speed estimation; AC: Attenuation coefficient; HRI: Hepato-renal index; NS: Non-significant.